-
(1R,2S,10S,11S,14R,15S,17S)-1-fluoro-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-5-one
-
ChemBase ID:
569
-
Molecular Formular:
C21H29FO5
-
Molecular Mass:
380.4503632
-
Monoisotopic Mass:
380.19990225
-
SMILES and InChIs
SMILES:
F[C@]12[C@H]([C@H]3[C@@]([C@](O)(CC3)C(=O)CO)(C[C@@H]2O)C)CCC2=CC(=O)CC[C@]12C
Canonical SMILES:
OCC(=O)[C@@]1(O)CC[C@@H]2[C@]1(C)C[C@H](O)[C@]1([C@H]2CCC2=CC(=O)CC[C@]12C)F
InChI:
InChI=1S/C21H29FO5/c1-18-7-5-13(24)9-12(18)3-4-15-14-6-8-20(27,17(26)11-23)19(14,2)10-16(25)21(15,18)22/h9,14-16,23,25,27H,3-8,10-11H2,1-2H3/t14-,15-,16-,18-,19-,20-,21-/m0/s1
InChIKey:
AAXVEMMRQDVLJB-BULBTXNYSA-N
-
Cite this record
CBID:569 http://www.chembase.cn/molecule-569.html
NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
(1R,2S,10S,11S,14R,15S,17S)-1-fluoro-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-5-one
|
(1R,2S,10S,11S,14R,15S,17S)-1-fluoro-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.02,7.011,15]heptadec-6-en-5-one
|
|
|
IUPAC Traditional name
|
|
Brand Name
|
9 .Alpha. Ff
|
9 Alpha Ff
|
9 alpha-Fludrocortisone
|
9 alpha-Fluorocortisol
|
9.Alpha.-Fluorocortisol
|
9.Alpha.-Fluorohydrocortisone
|
Alflorone
|
Astonin-H
|
F-COL
|
F-Cortef
|
Florinef
|
Fludrocortisona [INN-Spanish]
|
Fludrocortisone Acetate
|
Fludrocortisonum [INN-Latin]
|
Fludrocortone
|
Fludrone
|
Fludronef
|
Fluodrocortisone
|
Fluohydrisone
|
Fluohydrocortisone
|
Fluorocortisol
|
Fluorocortisone
|
ZK5
|
|
|
Synonyms
|
Fludrocortisone
|
(11β)-9-Fluoro-11,17,21-trihydroxypregn-4-ene-3,20-dione
|
9α-Fluorohydrocortisone
|
9α-Fluoro-17-hydroxycorticosterone
|
Fluohydrisone
|
Astonin H-d5
|
NSC 11318
|
|
|
CAS Number
|
|
PubChem SID
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
Data Source
|
Data ID
|
Price
|
TRC
|
|
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
ALOGPS 2.1
Acid pKa
|
12.550707
|
H Acceptors
|
5
|
H Donor
|
3
|
LogD (pH = 5.5)
|
1.3187733
|
LogD (pH = 7.4)
|
1.3187703
|
Log P
|
1.3187734
|
Molar Refractivity
|
96.928 cm3
|
Polarizability
|
38.038094 Å3
|
Polar Surface Area
|
94.83 Å2
|
Rotatable Bonds
|
2
|
Lipinski's Rule of Five
|
true
|
Log P
|
1.35
|
LOG S
|
-3.23
|
Solubility (Water)
|
2.24e-01 g/l
|
DETAILS
DETAILS
DrugBank
TRC
DrugBank -
DB00687
|
Item |
Information |
Drug Groups
|
approved |
Description
|
A synthetic mineralocorticoid with anti-inflammatory activity. [PubChem] |
Indication |
For partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenogenital syndrome. |
Pharmacology |
Fludrocortisone is a synthetic adrenocortical steroid possessing very potent mineralocorticoid properties and high glucocorticoid activity. It is indicated as partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison’s disease and for the treatment of salt-losing adrenogenital syndrome. The physiologic action of fludrocortisone acetate is similar to that of hydrocortisone. However, the effects of fludrocortisone acetate, particularly on electrolyte balance, but also on carbohydrate metabolism, are considerably heightened and prolonged. Mineralocorticoids act on the distal tubules of the kidney to enhance the reabsorption of sodium ions from the tubular fluid into the plasma; they increase the urinary excretion of both potassium and hydrogen ions. |
Toxicity |
Effects of overexposure include irritation, cardiac edema, increased blood volume, hypertension, cardiac arrhythmias, enlargement of the heart, headaches, and weakness of the extremities. |
Affected Organisms |
• |
Humans and other mammals |
|
Biotransformation |
Hepatic, some renal. |
Half Life |
3.5 hours |
Protein Binding |
High |
External Links |
|
|
PATENTS
PATENTS
PubChem Patent
Google Patent